



## Akero Therapeutics to Participate in Upcoming Virtual Healthcare Conferences in March

February 23, 2021

SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of its management team will participate in the following virtual investor conferences in March:

- **Cowen 41st Annual Healthcare Conference** on Tuesday, March 2, 2021
- **2021 H.C. Wainwright Global Life Sciences Conference** on Tuesday, March 9, 2021

A live webcast, if recorded, of Company presentations and Q&A will be available through the investor relations section of the Company's website at [www.akerotx.com](http://www.akerotx.com). Following the live webcasts, archived replays will be available on the Company's website.

### About Akero Therapeutics

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead program, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH. Akero is headquartered in South San Francisco. Visit us at [www.akerotx.com](http://www.akerotx.com) for more information.

### Investor Contact:

Christina Tartaglia  
212.362.1200  
[IR@akerotx.com](mailto:IR@akerotx.com)

### Media Contact:

Jennifer Weismann  
612-716-0556  
[media@akerotx.com](mailto:media@akerotx.com)



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/akero-therapeutics-to-participate-in-upcoming-virtual-healthcare-conferences-in-march-301233943.html>

SOURCE Akero Therapeutics